EUVIMEDEUVIMED entdecken
Leitlinie

Two conflicting guidelines on prostate specific antigen screening in Japan

Takeshi Takahashi iD

Japanese Journal of Clinical Oncology · 2023

DOI: 10.1093/jjco/hyac192 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Japanese Journal of Clinical Oncology, 2023. Verfasst von Takeshi Takahashi. Beteiligte Einrichtung: Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Japanese urologists need to listen seriously to the opinions of public health physicians and it is necessary to properly inform people of prostate specific antigen screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansJapanEarly Detection of CancerMass Screening

Stichwörter der Autor:innen

health insurancehealth policyoverdiagnosisprostate cancerprostate specific antigen screening

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, Japan.

ORCID-Profile: Takeshi Takahashi

Zitieren

APA

Takahashi, T. (2023). Two conflicting guidelines on prostate specific antigen screening in Japan. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyac192

Vancouver

Takahashi T. Two conflicting guidelines on prostate specific antigen screening in Japan. Japanese Journal of Clinical Oncology. 2023. doi:10.1093/jjco/hyac192

BibTeX
@article{Takahashi2023,
  author = {Takahashi, Takeshi},
  title = {Two conflicting guidelines on prostate specific antigen screening in Japan},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1093/jjco/hyac192}
}
Kostenlos starten →